What? A Cough Medicine for Depression?

Dr. Tracy Marks discusses a new FDA-approved depression medication, Avellity, which combines dextromethorphan and bupropion. Unlike traditional antidepressants, Avellity targets NMDA receptors to address neuroplasticity and the default mode network, offering rapid symptom relief. The video compares Avellity to ketamine, highlighting its fast action without the need for extensive monitoring. Avellity's unique formulation allows for sustained effects, unlike over-the-counter dextromethorphan. The video also touches on the potential for addiction if misused.

Describe how the default mode network is related to negative thought patterns in depression.

In what ways does Avellity provide a faster response compared to traditional antidepressants?

What challenges are associated with accessing ketamine for depression treatment?